Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of CD19 Chimeric Antigen Receptor T Cells for Pediatric Patients With CD19-positive B-cell Acute Lymphoblastic Leukemia Who Are Indicated for Hematopoietic Stem Cell Transplantation

NCT06247501 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT06247501
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06247501 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of CD19 Chimeric Antigen Receptor T Cells for Pediatric Patients With CD19-positive B-cell Acute Lymphoblastic Leukemia Who Are Indicated for Hematopoietic Stem Cell Transplantation
Lead sponsor
Seoul National University Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
January 19, 2024
Completion date
December 31, 2029
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cd19 car-t therapy, very high risk acute lymphoblastic leukemia